证监会亮剑：长药锁定退市、立方遭警示，火中取栗式炒作遭棒喝

Core Viewpoint - *ST Changyao has been officially recognized by the regulatory authority for systematic false reporting in its annual reports from 2021 to 2023, leading to imminent forced delisting due to major violations [1][3][5]. Group 1: Financial Misconduct - *ST Changyao has been found to have inflated revenue by CNY 215 million, CNY 284 million, and CNY 234 million for the years 2021, 2022, and 2023 respectively, with these figures representing 9.12%, 17.57%, and 19.51% of the disclosed revenue for those years [4]. - The company also inflated total profit by CNY 56.4 million, CNY 63.4 million, and CNY 43.7 million for the same years, accounting for 35.62%, 88.23%, and 6.42% of the total disclosed profit [5]. - The financial misconduct originated from a 2020 acquisition of 52.75% of Hubei Changjiang Star Pharmaceutical Co., which led to false revenue recognition through fabricated documents [3][4]. Group 2: Regulatory Actions and Consequences - The China Securities Regulatory Commission (CSRC) has issued a penalty of CNY 10 million and mandated corrections due to the financial misreporting [5]. - *ST Changyao is facing multiple delisting risks, including major violations, financial delisting, and trading delisting, with its net assets reported as negative [6]. - The stock has been trading below CNY 1 for 17 consecutive days, nearing the threshold for forced delisting if it continues for 20 days [6][7]. Group 3: Market Behavior and Investor Risks - Despite the significant risks and multiple warnings about potential delisting, *ST Changyao's stock price has surged, with a cumulative increase of over 100% in a short period [1][7]. - Similar patterns are observed in *ST Lifang, which is also under scrutiny for financial misconduct, with its stock price experiencing unusual volatility [7][8]. - The trading activity for both companies has shown a turnover rate exceeding 250%, indicating speculative trading behavior, with net selling from major funds [9].